Current Treatment of Bacterial Vaginosis—Limitations and Need for Innovation Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
I am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Bacterial Vaginosis
Bacterial Vaginosis
Bacterial vaginosis (BV) is caused by an imbalance in the vaginal microbiota, where the typically dominant Lactobacillus species are significantly reduced, leading to an overgrowth of anaerobic and facultative bacteria.
-
Women’s Health
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
-
Divine Aleru
Researched by:
-
Divine Aleru
ID
Divine Aleru
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What was Reviewed?
This comprehensive review critically examines the current limitations in bacterial vaginosis (BV) treatment, with particular focus on the high recurrence rates following standard antibiotic therapies, including both metronidazole and clindamycin. The authors analyze the microbial factors contributing to treatment failure, specifically the role of polymicrobial biofilms and antimicrobial resistance patterns in Gardnerella vaginalis and other BV-associated bacteria. The review also explores emerging evidence for sexual transmission of BV-associated microorganisms and evaluates novel therapeutic approaches targeting biofilm disruption and partner treatment strategies.
Who was Reviewed?
The review synthesizes data from multiple clinical trials and observational studies involving women with recurrent BV across diverse populations. It incorporates microbiological research on vaginal and penile microbiota, including studies demonstrating the presence of BV-associated bacteria in male sexual partners. The analysis also examines in vitro studies of biofilm formation and disruption, as well as limited clinical trials of adjunctive therapies like boric acid and probiotics.
Key Findings and Microbial Associations
The review highlights that BV represents a profound dysbiosis where protective Lactobacillus species, particularly L. crispatus, are replaced by a polymicrobial consortium including Gardnerella vaginalis, Atopobium vaginae, and various Clostridiales species. These pathogens form resilient biofilms that protect them from both metronidazole and clindamycin, the two first-line antibiotics for BV. While short-term cure rates approach 80% for both medications, recurrence rates exceed 50% within 6-12 months. The review notes important differences between the antibiotics: clindamycin appears more effective against certain biofilm-embedded pathogens like A. vaginae but may promote clindamycin-resistant anaerobic gram-negative rods, while metronidazole faces challenges with intrinsically resistant G. vaginalis clades. Both antibiotics fail to address the potential sexual transmission of BV-associated bacteria, which are detectable in male partners’ genital microbiota and may contribute to reinfection.
Implications of the Review
The review underscores that current antibiotic regimens, whether using metronidazole or clindamycin, are insufficient for long-term BV control due to biofilm persistence and potential sexual transmission. Clinicians should continue following treatment guidelines but recognize these limitations when managing recurrent cases. The findings suggest several important considerations: vaginal clindamycin may be preferable for certain BV subtypes or in pregnancy, while metronidazole remains the most widely studied option. For recurrent BV, adjunctive approaches like biofilm disruptors (boric acid, DNase) or partner treatment may be worth considering, though more research is needed. The review emphasizes the need for improved diagnostics to identify BV subtypes and resistance patterns, as well as the development of combination therapies targeting both pathogens and biofilms. Public health measures promoting condom use and further research into sexual transmission dynamics could help reduce BV recurrence at the population level.
Bacterial Vaginosis
Bacterial vaginosis (BV) is caused by an imbalance in the vaginal microbiota, where the typically dominant Lactobacillus species are significantly reduced, leading to an overgrowth of anaerobic and facultative bacteria.